ffi

Vivir'*ed
For lmmediate Release

November 29,2016

Vivimed's FDF facllity in Al*thxr completed successful USFDA inspection

All of the Company's manufacturing plants focussed on the regulated markets have
been inspected with a favourable outcome, over the last two years
Hyderabad, India, November 29,2016 - Vivimed Labs Limited ("Vivimed" or the Company), a niche
Specialty Chemicals and Pharmaceuticals company, announced today that its FDF manufacluring
facility located in Alathur, near Chennai has had a favourable outcome post its US Food and Drug
Administration (USFDA) inspection. The audit was conducted during the last week of November and
concluded on November 28,2016.

for Metronidazole and same is commercialised.

During November 2016, the Company acquired ANDA of Zolpidem and the file transfer has
successfully been completed. lt is expected to be commercialised by Q4 FY2O17. Vivimed is on track
of its filing targets and has successfully completed 3 ANDA filings during FY2017 and expect one
more filing to be completed by Q4 FY2017. These products provide vertical integration with the inFurthermore, Vivimed obtained ANDA approval

house APls.

cdtnmeriting on the deveiopment, Mr. santosh varalwar, Managing Director said:

'':

^Over the pa,si two years we have received safisfacf ory outcomes of USFDA inspection for our two
Blants in Spain, one in Mexico and one in tndia. For the lndia ptant, fhis was the second inspection,

a18 we ,.re delightea ny the outcome as fhis is reflection of the efforts of our team to constanily
l_e,uels of,regulatory compliance. We betieve that fhis saflsfactory outcome wiil supporl
o_i.;r e$ehu{<!"yi fo,'*further strengthen our positioning in the gtobal markets. We are on track with our
filinO,s.,2i2e.line wlic! are expected to bear fruits when these producfs sfarf to commercialise over the
next 1'8-24 months."

mplhtaffiigh

Analyst and lnvestor Enquiries

Ramesh Challa, CFO

Vivimed Labs Limited

Saket Somani
Churchgate Partners

ra m e s

c h a,,

"

3,: ri: :J;;':""t;

+91 22 6'169 59BB
com

V iv i m ed @c h u rch g ate p a rt n e rs i n d ia.

For further information on Vivimed, vrsit w.yw.vivir!.edlabg.com

Safe Harbour

of strategic initiatives, and other sfalemenfs relating lo ,ri!':rr,:,rr:s future business developments and economrc pertormanee

While these forward looking statements indicate our assessme nt and future expectations concerning
the devetopment of our
busrness, a number of risks, uncertainties and other unknown factors could cause actual devetopnients
and resutts to differ
materially lrom our expectations. These factors include, but are not tim1ed to, generail market,
macroeconomic,
governmental and regulatory trends, movements in currency exchange and interest
rates, compelll/ye pressures,
technological developments, changes in the financiat conditioni of third
farties dealing with us, legistative developments,
and other key factors that could affect ourbuslness and financial perlormance. Vivimei underlakes-no
obtigation to pubticly
revise any forward looking slafernenls to reflect future / likety events or circumstances

l lPage

WXy'wttrW
| /(l al
V\J

\J

Cornpany .Secretary
t